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Abstract
The structural similarity with plasminogen as well as thrombogenic and atherogenic in vitro functions raise the question
if lipoprotein(a) (Lp(a)) is a risk factor for venous thromboembolism (VTE) and ischemic stroke. Numerous case–control
and prospective studies using different cut-off values to define high Lp(a) generated conflicting evidence for both VTE
and ischemic stroke. Several meta-analyses demonstrated independent associations of elevated Lp(a) with a history of
VTE or ischemic stroke. However, the evidence of prospective studies for associations of Lp(a) with incident stroke
or recurrent VTE remains inconclusive. For ischemic stroke, data suggest that Lp(a) increases the risk of large-artery
atherosclerosis stroke, but not cardioembolic or lacunar stroke. Lp(a) may increase the risk of VTE in the presence of
additional thrombophilic risk factors. Larger cohort studies are needed to elaborate the importance of higher Lp(a) cut-offs
and interactions with other risk factors and subgroups of stroke or VTE. The value of Lp(a) to estimate residual vascular
risk after the first thromboembolic event remains to be adequately explored.
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Lipoprotein(a) [Lp(a)] resembles to low-density lipoprotein
(LDL) by the presence of one molecule apolipoprotein B
(apoB) and its relatively high content of cholesteryl esters
in the core. These features lend several in vitro athero-
genic properties to Lp(a) which are also exerted by LDL,
for example proteoglycan binding and induction of foam
cell formation [1]. Lp(a) differs from LDL by the pres-
ence of an additional apolipoprotein, termed apolipopro-
tein(a) (apo(a)), which is covalently bound to apoB by one
disulfide bond. Apo(a) is homologous to plasminogen by
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the presence of kringle IV and kringle V domains as well
as a protease domain, which however is catalytically in-
active. A variable number of repeat polymorphism of the
kringle IV domain encodes for 40 apo(a) isoforms which
differ by size and whose number is inversely correlated
with Lp(a) plasma concentrations [2]. The similarity to plas-
minogen as well as the presence of oxidized phospholipids
have been made responsible for the thrombogenic proper-
ties of Lp(a) which include the inhibition of fibrinolysis, the
induction of plasminogen activator inhibitor type 1 (PAI-1)
expression in endothelial cells, as well as the increasing
of activity of tissue factor pathway inhibitor and platelet
responsiveness [3].
These properties have led to the hypothesis that elevated
plasma levels of Lp(a) increase the risk of ischemic stroke
and venous thromboembolism (VTE).
Stroke
Stroke is an acute and potentially life-threatening disease
caused by the loss of cerebral blood supply leading to focal
cerebral ischemia and ultimately to cell death of the cen-
tral nervous system [4]. Worldwide, stroke is considered
the second most common cause of death and one of the
leading causes of disability in adult life [5]. Opposed to
hemorrhagic stroke (i. e. intracerebral hemorrhage), more
than 80% of all stroke cases are ischemic stroke events and
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are caused by occlusion of brain-supplying arteries. Despite
current secondary prevention strategies, the risk of recur-
rent stroke events remains high within the first years after
stroke [6]. The heterogeneous etiology of ischemic stroke
leads to the distinction of subgroups of ischemic stroke [7].
According to the most commonly used Trial of ORG 10172
in Acute Stroke Treatment (TOAST) classification [7], is-
chemic stroke can be caused by large-artery atherosclerosis,
cardioembolic events, small artery occlusion (i. e. lacunar
stroke), other causes (e.g. arterial dissection), or unknown
(cryptogenic) or competing causes. Of note, in population-
based studies large-artery atherosclerosis represent <20%
of all stroke events, whereas cryptogenic strokes represent
30–40% [8]. High blood pressure, presence of atrial fib-
rillation, and dyslipidemia (among others) are established
risk factors for ischemic stroke; however, the causal role of
Lp(a) in ischemic stroke is controversial.
Ischemic stroke and lipoprotein(a)
A significant association between high Lp(a) levels and in-
creased risk of ischemic stroke was expected for a long
time and first clinical reports date back to the mid-1980s [9,
10]. However, a nested case–control study using prospec-
tively collected plasma samples from the Physicians Health
Study published by Ridker and colleagues in 1995 found
no association between Lp(a) and the risk of future stroke
among healthy, middle-aged men [11]. Despite the nega-
tive finding of this study, a great number of case–control
and several prospective studies examining different cohorts
have reported varying results since [12, 13].
So far, three meta-analyses [14–16] summarized the
existing evidence regarding Lp(a) and stroke from both
case–control and prospective studies. All three meta-analy-
ses demonstrated a significant and independent association
of elevated Lp(a) with increased risk of ischemic stroke.
The largest meta-analysis performed by the Emerging Risk
Factor Collaboration [15] analyzed individual patient data
from 13 prospective studies comprising 1684 first-ever
ischemic stroke patients. After adjustment for confounding
variables, an increase per 3.5-fold (1 standard deviation)
higher usual Lp(a) level resulted in an adjusted risk ra-
tio of 1.11 (95% confidence interval [95% CI] 1.02 to
1.20) indicating Lp(a) to be a modest, continuous, and
independent risk factor for ischemic stroke. No analyses
were performed on specific ischemic stroke subgroups.
The most recent meta-analysis assessed generic data of
both prospective and observational studies and aimed to
explore subgroup-specific risk differences [16]. The meta-
analysis of nine prospective studies demonstrated an ad-
justed relative risk (RR) of 1.29 (95% CI 1.06 to 1.58) for
ischemic stroke when comparing high vs. low Lp(a) levels.
The analyses revealed a strong heterogeneity between the
studies. In fact, studies that chose categorical cut-off values
to define elevated Lp(a) levels (comparing very high vs.
very low Lp(a) levels) reported greater relative risks for
ischemic stroke, compared to studies analyzing continuous
relationships (e.g. change in risk per 1 standard deviation
increase in Lp(a) level). Furthermore, subgroup-specific
analyses revealed that greater relative risks in studies inves-
tigating younger individuals. In line with this observation
are previously published studies assessing the risk of high
Lp(a) in pediatric stroke that report much higher risk ratios
[17]. It may be argued that this fact is due to the low abso-
lute risk that is present in younger stroke patients overall.
The performed meta-regression in the latest meta-analy-
ses attributed some of the observed heterogeneity among
case–control studies to subtypes of ischemic stroke. Studies
that investigated patients with large artery atherosclerosis
or cryptogenic stroke demonstrated greater odds ratios than
studies involving stroke patients of other cause. Thus, it
seems to be important to investigate the role of Lp(a) in
specific subgroups of ischemic stroke.
Ischemic stroke subgroups
Many previously published studies investigating the risk of
stroke of patients with elevated levels of Lp(a) fail to re-
port the underlying cause of the stroke event. As stroke
etiologies vary substantially between cohorts, this fact may
explain some of the inconsistent results reported in the lit-
erature. For example, the prospective Atherosclerosis Risk
in Communities (ARIC) study examined 14,221 individu-
als free of cardiovascular disease and investigated the risk
of ischemic stroke with high levels of Lp(a) defined as
the 80th percentile of the cohort [18]. After an average
follow-up of 13.4 years 531 ischemic stroke events had
occurred. Comparing different stroke subtypes, high Lp(a)
increased the adjusted risk for non-lacunar stroke (RR 1.42,
95% CI 1.10 to 1.84), but not for lacunar stroke (RR 1.16,
95% CI 0.75 to 1.80) or cardio-embolic stroke (RR 1.07,
95% CI 0.65 to 1.74). Similarly, a more recent analysis of
the ARIC study found that Lp(a) levels >50mg/dl increase
the relative risk of stroke by 42% among individuals with-
out atrial fibrillation, but not among patients with present
atrial fibrillation reinforcing a pathological role of Lp(a)
primarily in atherothrombotic (atherosclerotic) stroke [19].
This assumption is supported by a previous Korean study
where higher Lp(a) levels were found in patients with large-
artery atherosclerotic stroke compared to patients with other
stroke subtypes [20]. The authors also demonstrated a sig-
nificant correlation of Lp(a) levels with the degree of in-
tracranial and extracranial carotid stenosis. Further evidence
is provided by a previous genetic study that investigated
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the association of ischemic stroke risk with two variants
(rs10455872 and rs3798220) of the apolipoprotein (a) gene
(LPA). Among 9396 stroke patients that were analyzed, the
odds ratio per variant allele was 1.27 (95% CI 1.11 to 1.46)
for large-artery atherosclerotic stroke, 1.03 (95% CI 0.88 to
1.22) for cardioembolic stroke, and 1.06 (95% CI 0.90 to
1.24) for lacunar stroke.
Risk of recurrent ischemic events
So far, only few studies have investigated the residual risk
of first-ever ischemic stroke patients with high levels of
Lp(a). One study comprising 250 first-ever, acute stroke
patients found an increased risk for the composite endpoint
of recurrent stroke, transient ischemic attack, myocardial
infarction, revascularization procedures, or cardiovascular
death after one year with high Lp(a) defined at a cut-off
level of 30mg/dl (adjusted odds ratio [OR] 2.60, 95% CI
1.19 to 5.47) [21]. Interestingly, most of the recurrent vas-
cular events occurred during the first months after the index
stroke. Using the same cut-off level of 30mg/dl, a recent
Chinese study demonstrated an increased risk of recurrent
ischemic stroke events at follow-up three months after the
index stroke (adjusted OR 2.58, 95% CI 1.11 to 6.01) [22].
Future studies with larger cohorts are needed to investigate,
if high Lp(a) levels increase the risk of recurrent vascular
events, especially within the first months after the index
event.
Venous thromboembolism in adults
The majority of studies which investigated the association
of Lp(a) with VTE were cross-sectional rather than prospec-
tive. The most recent meta-analysis analyzed the data of
ten studies encompassing 13,541 subjects of whom 5660
had a history of deep vein thrombosis and/or pulmonary
embolism [23]. As the cut-off defining elevated Lp(a), the
authors used the upper limit of the manufacturer’s product
reference range (usually 30mg/dL) in nine studies and the
75th percentile of Lp(a) value in the control group in one
study. With these definitions, elevated Lp(a) was associated
with the presence of VTE at an odds ratio of 1.56 (95% CI
1.36 to 1.79). Much stronger risk associations were found
in patients who have a very high risk of VTE, for example
patients immobilized due to paraplegia. In a case–control
study of 279 Chinese patients with spinal cord injury of
whom 55 had a VTE, an Lp(a) level >30mg/dL was as-
sociated with a more than 10-fold increased risk of VTE
(multivariate OR 10.35, 95% CI 2.37 to 45.15) [24].
In contrast to case–control studies, the data of prospec-
tive studies are more controversial. Among 8960 partici-
pants of the Copenhagen City Heart Study, of whom 735
experienced a VTE event during 15 to 18 years of follow-
up, Kamstrup et al. did not find any significant association
of Lp(a) levels with the incidence of VTE. Adjusted haz-
ard ratios for second (median, IQR: 17, 12–27mg/dl) and
third tertiles (median, IQR: 59, 40–94mg/dl) vs. first ter-
tile of Lp(a) (median, IQR: 3,1–5mg/dl) were 1.1 (95% CI
0.8–1.4) and 0.8 (95% CI 0.6–1.1), respectively [25]. Like-
wise, in a 12-center study of 510 patients with first unpro-
voked VTE treated for 5–7 months with anticoagulants and
followed up for 16.9± 11.2 months, Rodgers et al. did not
find any significant association of Lp(a) levels >300mg/L
with risk of recurrent VTE events (relative risk 1.4, 95%
CI 0.7–2.6) [26]. Conversely, in a study of 467 patients
with first VTE followed up for one year, Marcucci et al.
found a 5-fold increased risk of recurrent VTE for Lp(a)
>30mg/dL (OR 5.1, 95% CI 3.1–8.4) which was similar to
that for hyperhomocysteinemia and even higher than that
for factor V Leiden or the factor II 20210GA polymorphism
[27].
Mendelian randomization studies also made controver-
sial findings on the association of LPA polymorphisms with
risk of VTE. Kamstrup and colleagues [25] excluded any
contribution of the kringle IV repeat polymorphism to VTE
in the Copenhagen City Heart Study (N= 9190, 443 events)
and the Copenhagen General Population study (N= 28,538;
926 with history of VTE). Of note, in the same study, the
authors found genetically causal associations of Lp(a) levels
and kringle IV repeats with coronary, carotid and femoral
atherosclerosis as well as of factor V Leiden with VTE
[25]. A more recent but smaller study of 516 patients with
a history of VTE and 1117 controls found significant in-
verse and dose-dependent associations of kringle IV repeat
numbers with venous thrombosis [28].
Venous thromboembolism in children and
adolescents
With an annual incidence of less than 1 in 100,000, VTE
is a rare condition in childhood and adolescence. Never-
theless, several studies have investigated the associations of
Lp(a) and other thrombophilic risk factors with the presence
and recurrent incidence of VTE in this young population.
A meta-analysis of eight studies encompassing 589 pa-
tients with VTE and 1441 controls, Lp(a) levels >300mg/L
was associated with a 4.5-fold higher risk of first VTE (95%
CI 3.19 to 6.35) [29]. One of the studies included also in-
vestigated the association of the kringle IV repeat poly-
morphism with VTE. In 186 patients with VTE and 186
matched controls the highest quartile of Lp(a) levels and
the lowest quartile of kringle IV repeats were associated
with similar risks of VTE (7.68 vs. 8.14) [30]. Also the
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history of cerebral venous thrombosis in childhood was as-
sociated with elevated Lp(a) significantly (multivariate OR
4.1; 95% CI 1.9–8.6) and even more strongly than with
factor V Leiden or the 20210GA polymorphism [31].
A meta-analysis of six studies with 135 recurrent VTEs
among 1155 children and adolescents followed up for a me-
dian time of 48 months (minimum, 12 months; maximum,
96 months) after the first VTE did not find any significant
association of high Lp(a) levels with the risk of recurrent
VTE events (OR 0.84; 95% CI 0.5 to 1.4). However, in this
meta-analysis neither factor V Leiden nor the prothrombin
polymorphism were significantly associated with the risk
of recurrent VTE. Only the combination of at least two
thrombophilic risk factors including elevated Lp(a) evolved
as a prognostic risk factor for recurrent VTE (OR 4.91;
95% CI 3.12 to 7.74) [29]. One of the studies followed
up 301 young patients with start of anticoagulation within
6 months after first VTE and assessed 54 recurrent VTEs
within 6 months to 15 years of follow-up [32]: Elevated
Lp(a) per se did not significantly increase the risk of recur-
rent VTE (OR,: 1.35; 95% CI,: 0.85–2.13). However, the
combination of Lp(a) >300mg/L with at least one other
thrombophilic risk factor (factor V Leiden, prothrombin
20210GA, MTHFR 677TT, protein C deficiency, protein S
deficiency, or antithrombin deficiency) increased the risk of
VTE by factor 2.36 (95% CI 1.51–3.68) [32]. The strongest
risk factor was the combination of elevated Lp(a) with fac-
tor V Leiden which increased the risk of recurrent VTE by
factor 6.2 [32].
Conclusions
Lp(a) has been shown to be an independent and modest
risk factor for ischemic stroke in recent meta-analyses of
prospective studies. Overall, the relative risk is increased by
approximately 30%; however, the reported differences vary
according to the examined population including stroke sub-
type and the applied statistical methodology. Data suggest
that Lp(a) is primarily increasing the risk of large-artery
atherosclerosis stroke. Nevertheless, controversial literature
and limited therapeutic options detain current guidelines to
recommend the routine measurement of Lp(a) after stroke
[33].
The role of Lp(a) as a thrombophilic risk factor remains
even more equivocal: the meta-analyses of cross-sectional
studies revealed significant associations of Lp(a) >30mg/dl
with a history of VTE. However, data of genetic studies
on the associations of kringle IV repeats with VTE as well
as of prospective studies on associations of high Lp(a) lev-
els with recurrent VTE are controversial. Possibly, elevated
Lp(a) becomes a relevant thrombophilic risk factor if it
coincides with other hereditary thrombophilic risk factors
and/or thrombophilic basal conditions (e.g. long-term im-
mobilization).
Larger cohort studies are necessary to test whether higher
cut-off values than conventional 30mg/dl or 50mg/dl, in-
teractions with other risk factors, or etiological disease dif-
ferentiation are needed to firmly establish or rule-out any
role of Lp(a) as a risk factor of ischemic stroke or VTE.
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